Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etanercept - Pfizer

Next Previous
X
Search
Drug Profile

Etanercept - Pfizer

Alternative Names: Enbrel; p75TNFR-Ig; rhu TNFR-Fc; Soluble tumour necrosis factor receptor p75 Fc IgG1 fusion protein; TNF receptor fusion protein; TNFR-Fc-p75; TNR-001

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Pantec Biosolutions; Pfizer; University of Leeds
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Graft-versus-host disease
  • Phase II Discoid lupus erythematosus; Mucocutaneous lymph node syndrome
  • No development reported Metabolic syndrome
  • Discontinued Adult-onset Still's disease; Asthma; Behcet's syndrome; Cachexia; Granulomatosis with polyangiitis; Heart failure; Myasthenia gravis; Pulmonary fibrosis; Septic shock; Transplant rejection

Most Recent Events

  • 31 Dec 2022 Amgen has patent protection for formulations of etanercept and methods of preparing formulations in USA
  • 29 Nov 2022 No development reported - Phase-III for Psoriatic arthritis in Argentina (SC)
  • 29 Nov 2022 No development reported - Phase-III for Psoriatic arthritis in Chile (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top